Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
Authors
Keywords
-
Journal
GUT
Volume -, Issue -, Pages gutjnl-2020-321175
Publisher
BMJ
Online
2021-01-25
DOI
10.1136/gutjnl-2020-321175
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer
- (2020) Arianna Fumagalli et al. Cell Stem Cell
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts
- (2019) Maartje van der Heijden et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation
- (2019) Kazuto Harada et al. ANNALS OF SURGERY
- Lineage tracing and targeting of IL17RB+tuft cell-like human colorectal cancer stem cells
- (2019) Norihiro Goto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
- (2018) Charissa Kim et al. CELL
- Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
- (2018) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer
- (2018) Kristiaan J. Lenos et al. NATURE CELL BIOLOGY
- YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer
- (2018) Fan Li et al. CLINICAL CANCER RESEARCH
- Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set
- (2018) N. del-Toro et al. Nature Communications
- Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
- (2017) Ishna N. Mistry et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Intra-tumor heterogeneity from a cancer stem cell perspective
- (2017) Pramudita R. Prasetyanti et al. Molecular Cancer
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Targeting the Colorectal Cancer Stem Cell
- (2017) Jan Paul Medema NEW ENGLAND JOURNAL OF MEDICINE
- Gastric adenocarcinoma
- (2017) Jaffer A. Ajani et al. Nature Reviews Disease Primers
- Post-Chemoradiation Surgical Pathology Stage Can Customize the Surveillance Strategy in Patients With Esophageal Adenocarcinoma
- (2017) Takashi Taketa et al. Journal of the National Comprehensive Cancer Network
- Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
- (2016) K.-W. Lee et al. CLINICAL CANCER RESEARCH
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
- (2015) V. Adorno-Cruz et al. CANCER RESEARCH
- The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
- (2015) S. Song et al. CLINICAL CANCER RESEARCH
- Esophageal and Esophagogastric Junction Cancers, Version 1.2015
- (2015) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- YAP and the drug resistance highway
- (2015) Alona Keren-Paz et al. NATURE GENETICS
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- (2015) Luping Lin et al. NATURE GENETICS
- Cancer Stem Cells: The Promise and the Potential
- (2015) Jaffer A. Ajani et al. SEMINARS IN ONCOLOGY
- Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties
- (2014) S. Song et al. CANCER RESEARCH
- Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer
- (2014) Kazuki Sudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Loss of TGF- Adaptor 2SP Activates Notch Signaling and SOX9 Expression in Esophageal Adenocarcinoma
- (2013) S. Song et al. CANCER RESEARCH
- Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy
- (2013) Anthony Linton et al. Clinical Genitourinary Cancer
- The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737
- (2013) Mariana Boiani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients
- (2013) J.A. Ajani et al. Molecular Oncology
- Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort
- (2012) N. K. S. Cheedella et al. ANNALS OF ONCOLOGY
- Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma
- (2012) W. W. Lockwood et al. CLINICAL CANCER RESEARCH
- Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
- (2011) A. Imai et al. CANCER RESEARCH
- Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis
- (2011) W. Kang et al. CLINICAL CANCER RESEARCH
- Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
- (2011) Neal Ready et al. Journal of Thoracic Oncology
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
- (2008) K. Balakrishnan et al. BLOOD
- ALDH1 as a Functional Marker of Cancer Stem and Progenitor Cells
- (2008) Julie Douville et al. STEM CELLS AND DEVELOPMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started